Iparomlimab and Tuvonralimab in HNSCC

Abroad (travel likely)RecruitingPHASE2

Conditions

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai Municipality, China
Contact: Study coordinator (Guoxin Ren, M.D.) · renguoxincn@sina.com · 13916948812

Study leads

Yue He, M.D.
Principal Investigator
the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer

Head and Neck Squamous Cell Carcinoma · Recurrent Head and Neck Squamous Cell Carcinoma · Metastatic Head-and-neck Squamous-cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Winston-Salem, United States

A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Chongqing, China · Chengdu, China

H101 Plus TACE for r/m HNSCC

Head and Neck Squamous Cell Carcinoma · Oncolytic Virus · TACE

Abroad (travel likely)RecruitingPHASE2

Chengdu, China

A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer

Head and Neck Cancer · Head and Neck Squamous Cell Carcinoma · Head and Neck Neoplasms

Abroad (travel likely)RecruitingPHASE2

Chicago, United States